An interventional study of Automated text message reminder in Hearing Loss, sponsored by Stanford University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Stanford University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 321 studies in Hearing Loss with a site in United States — 82 open to participants now, 94 under way, 3 of them phase 3. Hearing Loss · United States.
Among the 321 studies in Hearing Loss with a site in United States, this one is the 54th largest by planned enrollment of the 272 interventional ones that give a count, is one of 25 that started in 2026, is one of 212 with no phase, reaches primary completion later than 88 of the 93 other live ones, and was the 295th registered.
797 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.
Browse Hearing Loss studies →82 of the 321 studies in Hearing Loss with a site in United States are open now. Recruiting first, the newest first:
Sound Pharmaceuticals, Incorporated · Sites in United States
Ages 18+
Skylark Bio Inc. · Sites in United States
Ages 9 mo–7 yrs
University of Arizona · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 25–55 · Healthy volunteers
University of Arizona · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 125 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 43 (34%) stop at 75 or younger; 47 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
321 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 31 · Phase 3 5 · Phase 4 5
First in 1997; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 190 is above the median of 44 across 562 interventional studies indexed under Hearing Loss.
Median enrollment 48 across the 272 interventional studies, 79 across the 48 observational. Of the 203 that completed or were terminated, 99 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
104 of 321 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Stanford University has 4 studies filed under Hearing Loss — fewer than ten, so there is no comparison to draw.
34 of the studies in Hearing Loss with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06859788Phase 3Sound Pharmaceuticals, IncorporatedSPI-1005 for the Treatment of Meniere's Disease (Open Label) | 2026-12 |
| NCT05176561Gallaudet UniversityAuditory-Cognitive Training to Optimize Outcomes for Older CI Users | 2026-11 |
| NCT07913776Sonova AGPerformance of a Remote Microphone Compared to Hearing Aids Alone | 2026-11-30 |
| NCT05260307Boston University Charles River CampusImproving Spatial Perception and Speech Understanding in Multitalker Mixtures | 2026-11-30 |
| NCT06340633Sound Pharmaceuticals, IncorporatedSPI-1005 in Adults Receiving Cochlear Implant | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 321 studies in Hearing Loss with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Many individuals with hearing loss do not receive adequate hearing healthcare. Only about 30 percent of people that are found to have hearing loss during a hearing test go on to use hearing aids. The investigators propose to test the use of text message reminders to educate patients with hearing loss, and to encourage them to get hearing aids. The study objective is to examine whether automated text-messaging reminders increase the use of hearing aids among patients with hearing loss, who are hearing aid candidates.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in the intervention group will receive automated text messages instructing them to obtain hearing aids. The messages will also include basic information on the prevalence and negative effects of hearing loss.
Behavioral: Automated text message reminder
Participants in the intervention group will receive automated text messages instructing them to obtain hearing aids. The messages will also include basic information on the prevalence and negative effects of hearing loss.
Likelihood of obtaining hearing aids
Participants will be queried on whether they have obtained hearing aids since enrollment in the study. Participants who have not obtained hearing aids, will be asked to rate the likelihood that they would obtain hearing aids. Likelihood will be assessed on an 11-point visual analogue scale (VAS). Score range: 0 to 10 (0 = not likely, 10 = very likely). Participants who have already obtained hearing aids will be assigned a score of 10.
Time frame: This outcome data will be collected 3, 6, 9, and 12 months after enrollment.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Nov 2030, 48 months after the start.
Of 197 non-industry interventional studies with no phase under Hearing Loss, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 59. This study's planned 48 months is above that.
Counting every sponsor, half of 323 studies reached it within 19 months; a quarter within 5 and three quarters within 42.
Start moved twice since we started tracking on Sep 25, 2026: Nov 2025 → Nov 2026, last on Nov 12, 2026.
Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2027 → Nov 2030, on Oct 30, 2026.
Completion moved once since we started tracking on Sep 25, 2026: Nov 2027 → Dec 2030, on Oct 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.